According to IMARC Group’s latest report, titled “Choroidal Neovascularization Market: Industry Trends, Share, Size, Growth, Opportunity and Forecast 2021-2026,” the global choroidal neovascularization market reached a value of US$ 5.3 Billion in 2020. Looking forward, IMARC Group expects the market to grow at a CAGR of around 7% during 2021-2026.
Choroidal neovascularization (CNV) refers to the formation of new blood vessels in the eyes' choroid layer that affects the Bruch’s membrane and retinal pigment epithelium (RPE). It can occur due to several reasons, such as age-related macular degeneration, excess secretion of vascular endothelial growth factor, and numerous inflammatory diseases of choroid and retina. Some of the primary symptoms of CNV include lipid exudation, sub-retinal blood and fluid, loss of vision, color disturbances, waviness, and black spots in the central vision. Currently, various procedures, such as fluorescein angiography (FA), indo-cyanine green (ICG) angiography, and optical coherence tomography (OCT) scanning, are being adopted to diagnose CNV.
Request Free Sample Report:
https://www.imarcgroup.com/choroidal-neovascularization-market/requestsample
Market Trends
The global market for CNV treatment is driven by the growing occurrences of ocular histoplasmosis, pathologic myopia, angioid streaks, choroidal tears, etc. Furthermore, the rising geriatric population who are more vulnerable to severe eye-based disorders is also augmenting the market growth. Furthermore, several improvements in healthcare facilities, along with the increasing investments in extensive R&D activities in the medical sector, are also catalyzing the global market.
Ask Analyst and Browse Full Report with TOC & List of Figure: https://www.imarcgroup.com/choroidal-neovascularization-market
List of Key Companies Covered in this Market Report:
- Bausch Health Companies Inc.
- Bayer AG
- Gilead Sciences Inc.
- Hoffmann-La Roche Ltd.
- MaaT Pharma
- Novartis AG
- Pfizer Inc.
- Quark Pharmaceuticals Inc. (SBI ALApharma Co. Limited)
- Regeneron Pharmaceuticals Inc.
- Sanwa Kagaku Kenkyusho Co. Ltd. (Suzuken Co. Ltd.)
The report has segmented the market on the basis of product type, type of diagnosis, treatment type, application and geography.
Breakup by Product Type:
- Intravenous
- Intravitreal
Breakup by Type of Diagnosis:
- Fluorescein Angiography (FA)
- Indocyanine Green (ICG) Angiography
- Spectral Domain Optical Coherence Tomography (OCT)
- Others
Breakup by Treatment Type:
- Angiogenesis Inhibitors Injection
- Photodynamic Therapy
- Laser photocoagulation
- Low-dose Radiation Therapy
- Surgery
Breakup by Application:
- Extreme Myopia
- Malignant Myopic Degeneration
- Age-Related Developments
Breakup by Geography:
- North America (U.S. & Canada)
- Europe (Germany, United Kingdom, France, Italy, Spain, Russia, and Others)
- Asia Pacific (China, India, Japan, South Korea, Indonesia, Australia, and Others)
- Latin America (Brazil, Mexico)
- Middle East & Africa
Key highlights of the report:
- Market Performance (2015-2020)
- Market Outlook (2021- 2026)
- Porter’s Five Forces Analysis
- Market Drivers and Success Factors
- SWOT Analysis
- Value Chain
- Comprehensive Mapping of the Competitive Landscape
If you need specific information that is not currently within the scope of the report, we can provide it to you as a part of the customization.
About Us
IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.
IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.
Contact US
IMARC Group
30 N Gould St Ste R
Sheridan, WY 82801 USA - Wyoming
Email: Sales@imarcgroup.com
Tel No:(D) +91 120 433 0800 Americas:- +1 631 791 1145 | Africa and Europe :- +44-702-409-7331 | Asia: +91-120-433-0800, +91-120-433-0800
Follow us on Twitter: https://twitter.com/ImarcServices
